Literature summary for 3.4.21.89 extracted from

Smith, P.A.; Romesberg, F.E.
Mechanism of action of the arylomycin antibiotics and effects of signal peptidase I inhibition (2012), Antimicrob. Agents Chemother., 56, 5054-5060.

Search for more literature for 3.4.21.89

Application

Application	Comment	Organism
medicine	inhibition of enzyme by arylomycin A-C16 results in an insufficient flux of proteins through the secretion pathway leading to mislocalization of proteins. Inhibition results in synergistic sensitivity of cells when combined with an aminoglycoside. Antibiotics tetracycline, erythromycin, and vancomycin each interact additively with arylomycin A-C16, while rifampin and trimethoprim show pronounced antagonism	Staphylococcus aureus
medicine	inhibition of enzyme by arylomycin A-C16 results in an insufficient flux of proteins through the secretion pathway leading to mislocalization of proteins. Inhibition results in synergistic sensitivity of cells when combined with an aminoglycoside. No significant interactions are observed between arylomycin A-C16 and erythromycin, polymyxin B, trimethoprim, or ciprofloxacin. Arylomycin A-C16 shows mild synergism with cephalexin, pronounced synergism with rifampin and gentamicin, and antagonism with the translational inhibitor tetracycline	Escherichia coli

Inhibitors

Inhibitors	Comment	Organism	Structure
arylomycin A-C16	inhibition of enzyme results in an insufficient flux of proteins through the secretion pathway leading to mislocalization of proteins. Inhibition results in synergistic sensitivity when combined with an aminoglycoside	Escherichia coli
arylomycin A-C16	inhibition of enzyme results in an insufficient flux of proteins through the secretion pathway leading to mislocalization of proteins. Inhibition results in synergistic sensitivity when combined with an aminoglycoside	Staphylococcus aureus

Organism

Organism	UniProt	Comment	Textmining
Escherichia coli	-	-	-
Staphylococcus aureus	-	-	-

Use of this online version of BRENDA is free under the CC BY 4.0 license. See terms of use for full details.

Release 2023.1 (January 2023)